Tirofiban After Successful MT Recanalization in AIS (NCT06265051) | Clinical Trial Compass
CompletedPhase 2/3
Tirofiban After Successful MT Recanalization in AIS
China1,380 participantsStarted 2024-04-09
Plain-language summary
Acute ischemic stroke with large vessel occlusion is a frequently occurring life-threatening condition. Although endovascular treatment can effectively open occluded vessels, the successful reperfusion rate exceeds 80%, but the rate of good prognosis is less than 50%. The current clinical focus is on how to improve futile recanalization. Tirofiban is widely used in the treatment of stroke, as it can effectively prevent vascular reocclusion and improve microcirculation perfusion. It has the potential to improve futile recanalization, but there is a lack of high-level evidence-based medical support. This multicenter, prospective, double-blind, randomized controlled trial was conducted to assess the effectiveness and safety of sequential tirofiban therapy following successful mechanical thrombectomy within 24 hours of onset.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥18 years old;
✓. NIHSS score: 6-30;
✓. Symptom onset to random time of 24h, including wake-up stroke or unwitnessed stroke; The onset time of symptoms was defined as the last time of normal performance.
✓. mRS 0-1 before the stroke;
✓. Subject or legal representative can sign an informed consent form;
✓. Clinical symptoms caused by acute occlusion of the following sites confirmed by CTA or MRA: intracranial segment of ICA, M1 segment of middle cerebral artery, M2 trunk of middle cerebral artery;
✓. ASPECTS≥6 on NCCT or DWI;
✓. After the end of mechanical thrombectomy, the mTICI was stable at 2b/3, and there was no secondary embolism in other non-offending vessels, or the diagnostic angiography before mechanical thrombectomy showed that the occluded vessels improved to mTICI 2b/3, and no mechanical thrombectomy was planned.
Exclusion criteria
✕
What they're measuring
1
Proportion of patients functionally independent (mRS score 0 to 2) at 90 days
Timeframe: 90 days after randomization
2
Number of participants with symptomatic intracranial hemorrhage